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HCV p7 as a novel vaccine-target 
inducing multifunctional CD4+ and 
CD8+ T-cells targeting liver cells 
expressing the viral antigen
Jonathan Filskov1,2, Peter Andersen2, Else Marie Agger2 & Jens Bukh1
Despite recent treatment advances for chronic hepatitis C virus (HCV) infection, a vaccine is urgently 
needed for global control of this important liver pathogen. The lack of robust immunocompetent HCV 
infection models makes it challenging to identify correlates of protection and test vaccine efficacy. 
However, vigorous CD4+ and CD8+ T-cell responses are detected in patients that spontaneously resolve 
acute infection, whereas dysfunctional T-cell responses are a hallmark of chronic infection. The HCV p7 
protein, forming ion-channels essential for viral assembly and release, has not previously been pursued 
as a vaccine antigen. Herein, we demonstrated that HCV p7 derived from genotype 1a and 1b sequences 
are highly immunogenic in mice when employed as overlapping peptides formulated as nanoparticles 
with the cross-priming adjuvant, CAF09. This approach induced multifunctional cytokine producing 
CD4+ and CD8+ T-cells targeting regions of p7 that are subject to immune pressure during HCV infection 
in chimpanzees and humans. Employing a surrogate in vivo challenge model of liver cells co-expressing 
HCV-p7 and GFP, we found that vaccinated mice cleared transgene expressing cells. This study affirms 
the potential of a T-cell inducing nanoparticle vaccine platform to target the liver and introduces HCV p7 
as a potential target for HCV vaccine explorations.
Despite a remarkable success in the development of curative direct acting antiviral treatments for chronic hep-
atitis C virus (HCV) infection, an effective prophylactic vaccine is considered the only means to substantially 
reduce the burden of the global HCV epidemic causing at least 400,000 deaths annually1–3. Development of a 
vaccine has, however, proven to be an immense challenge and is hampered by the lack of suitable animal chal-
lenge models to test vaccine efficacy, the numerous ways through which the virus evades innate and adaptive 
immune responses, as well as the extensive genetic diversity of HCV4,5. Within an infected individual, HCV exist 
as a quasispecies often differing by 1–3% at the nucleotide and deduced amino acid level6,7. Globally, the genetic 
heterogeneity, which is around 30% across the HCV major genotypes, further complicates development of an 
effective pan-genotypic vaccine8–11. Potent antibody inducing vaccines have been used against a number of viral 
diseases, but seem on their own to be insufficient for protection against several viral infections causing chronic 
diseases, such as HCV, human immunodeficiency virus (HIV) and herpesviruses, which all exhibit a tremendous 
ability to evade immune surveillance12–14.
In addition to vaccines that generate neutralizing antibodies, development of vaccines that also induce specific 
T-cell responses might be required for viruses that develop into chronic infections, such as HCV15,16. Although 
the main focus in T-cell vaccine development has been on developing strong CD8+ T-cell responses, it is now 
becoming clear that CD4+ T-cells comprise an indispensable element of cellular immunity, not only key to estab-
lish and maintain multifunctional CD8+ T-cells, but also as effectors with direct antiviral potential17,18. Further 
supporting the protective roles of both subsets of T cells, vigorous and broad cellular CD8+ and CD4+ T-cell 
responses are observed in individuals who spontaneously clear acute HCV infection19–23.
Although the liver acts as a secondary lymphoid organ where priming of T-cells can take place, inefficient 
stimulatory signals and upregulated inhibitory surface molecules by antigen presenting cells in the liver, skew 
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cellular immunity towards tolerance or apoptosis24–26. Ideally, an HCV-vaccine should therefore facilitate efficient 
peripheral priming of T-cells with the ability to infiltrate and eliminate virus infected hepatocytes27,28. At present, 
the only HCV vaccine being evaluated in clinical trials is a potent CD4+ and CD8+ T-cell inducing adenoviral vec-
tor Chimp/MVA vaccine29,30. Alternative vaccine approaches such as peptide- and subunit vaccines are relatively 
easy to manufacture and store, are considered safe due to their simplicity and can readily be tailored to target- 
and combine specific antigen sequences31,32. These do, however, require co-administration of a suitable adjuvant 
in order to facilitate cross-presentation of exogenous antigens to MHC class I molecules on antigen presenting 
cells (APCs), e.g. through Toll-like receptor (TLR) engagement. One such example is the nanoparticle adjuvant, 
CAF09, that consists of cationic liposomes combined with the immunostimulants monomycolyl glycerol (MMG) 
and a TLR-3 ligand, Poly(I:C)33. This adjuvant efficiently drives antigen specific effector-like CD4+ and CD8+ 
T-cell responses with an IFN-γ+TNF-α+ double positive cytokine profile for a number of different antigens, and 
has also shown promising results when employed in prophylactic and therapeutic subunit cancer vaccines in pre-
clinical tumor models33. The induction of CD8+ T-cell responses depend, however, on the route of administration. 
It appears, that intraperitoneal injection permitting self-drainage from the site of injection to the draining lymph 
nodes is a prerequisite for the CAF09-adjuvated vaccine particles to reach lymph node resident TLR3+ CD8α 
dendritic cells (DCs) with the capacity to cross present exogenous antigen on MHC class I34. Current efforts focus 
on enhancing the physiochemical characteristics of the adjuvant nanoparticles to target lymph node resident DCs 
by subcutaneous and intramuscular vaccination routes, which are preferred for human use35.
HCV vaccine development has mainly focused on targeting HCV core, envelope- or the nonstructural 
NS3-NS5B proteins36,37. Here, we explore the HCV p7 as a vaccine antigen. This 63 amino acid long polypeptide 
belongs to the viroporin family that presumably serves as a transmembrane cationic ion channel upon oligomeri-
zation38. The p7 protein has been found to be crucial for efficient assembly, as well as release of infectious virions, 
and blocking with specific compounds can abrogate its function39,40. Importantly, p7 is also targeted by T cells in 
HCV patients and immune pressure against p7 can drive mutational escape from T-cell epitopes in chimpanzees 
experimentally infected with HCV15,41. Viral fitness is however tightly linked to alterations in the p7 sequence. 
Several amino acids of p7 are conserved within HCV genotypes as they are essential for p7 interaction with other 
genomic regions in a genotype-specific manner42. Additionally, regions that are critical for the structural function 
of the ion channel are highly conserved across genotypes39. Thus, p7 might represent an interesting target for 
antiviral therapy and vaccine development.
Here, we explore the potential of HCV p7 as a vaccine antigen by employing a nanoparticle-based vaccine- 
approach consisting of a panel of overlapping p7 peptides (pepmix) formulated in the CAF09 adjuvant43. The 
present study demonstrates that p7 is highly immunogenic and can be pursued to induce multifunctional CD4+ 
and CD8+ T-cells that efficiently targets the liver and eliminate hepatocytes that express the targeted HCV antigen.
Results
HCV p7-specific multifunctional CD4+ and CD8+ T-cell responses obtained through vaccination 
in mice. To investigate the potential of HCV p7 as a vaccine antigen and its ability to induce CD4+ and CD8+ 
T-cell responses, we compared a protein-based approach with an approach based on six overlapping peptides (pep-
mix) covering the entire p7 sequence of HCV strain J4 (genotype 1b)44. Figure 1a shows the amino acid sequence 
of the p7 protein (J4) and peptides contained in p7 pepmix (J4). The vaccine antigens were formulated in the cati-
onic adjuvant CAF0933. CB6F1 mice were immunized intraperitoneally three times at two-week intervals and the 
immune response was assessed two weeks after the final vaccination, as indicated on the timeline shown in Fig. 1b.
To assess the p7-specific T-cell responses, splenocytes were isolated and re-stimulated with a pool of the six 
overlapping p7 peptides used in the pepmix vaccination, followed by intracellular (IC) flow cytometry-analysis. 
Representative plots of CD44+CD4+ (Fig. 1c) and CD44+CD8+ (Fig. 1d) T-cells producing IFN-γ (upper panel), 
TNF-α (middle panel) and IL-2 (lower panels) are shown for controls (CAF09), as well as p7 protein (J4) and p7 
pepmix (J4) vaccinated mice. Whereas the p7 protein (J4)-based vaccine approach only induced antigen-specific 
CD4+ T-cells producing IFN-γ, TNF-α and IL-2, the p7 pepmix (J4) vaccine generated both robust CD4+ and 
CD8+ T-cell responses (Fig. 1e,f). Notably, escalating the p7 protein dose to equimolar antigen levels of peptides 
used in the p7 pepmix vaccine did not lead to induction of CD8+ T-cells (Supplementary Fig. S1).
p7 protein and p7 pepmix (J4) induced a similar repertoire of epitope specific CD4+ T cells. We 
have previously reported that vaccination with peptide panels could induce a broadened T cell response in a 
given genetic context43. To determine differences in the repertoire of epitope-specific T-cells induced with p7 
protein (J4) compared to pepmix (J4) in a CB6F1 background, splenocytes from vaccinated mice were stimu-
lated with each of the individual J4 peptides as indicated below the graphs in Fig. 2a. Here, we found that both 
vaccines generated CD4+ T-cell responses targeting epitopes within peptide #1, #3 and #4 (Fig. 2a, upper panel), 
whereas CD8+ T-cells recognizing peptide #4 were detected only after p7 pepmix (J4) vaccination (lower panel). 
An experiment in which mice were vaccinated with p7 pepmix based on HCV strain H77 (genotype 1a), revealed 
CD4+ and CD8+ T cells only targeting H77 peptide #4 (Supplementary Fig. S2). In silico prediction indicated the 
presence of strong CD8+ T cell epitopes within both the J4 and H77 sequence of the corresponding #4 peptide 
and that these were linked to a C57BL/6 background (Supplementary Table S1). The majority of peptide #4 spe-
cific CD107+ CD8+ T-cells were multifunctional in their capacity to co-produce IFN-γ and TNF-α indicating 
enhanced cytotoxic potential (Fig. 2b)45.
HCV p7 pepmix (J4) induced T-cells with in vivo cytotoxic capability. Next, we used the information 
of epitope-specific cellular responses to further evaluate the functional capabilities of CD4+ and CD8+ T-cells 
by assessing their cytotoxic capacity in vivo. To further decipher the MHC-restriction of targeted epitopes, we 
here immunized C57BL/6 or BALB/c mice with p7 pepmix (J4) rather than employing the CB6F1 offspring 
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cross. CD4+ T cell epitopes within peptide #4 were recognized in both mouse strains, whereas the epitope within 
peptides #1 and #3 was restricted to C57BL/6 and BALB/c backgrounds, respectively (Supplementary Figs S3a,b 
versus S4a,b). CD8+ T cell responses were only observed in C57BL/6 mice targeting peptide #4.
Figure 1. FACS-based frequency analysis of antigen-specific cytokine producing T-cells after vaccination with 
HCV p7 protein or pepmix. Amino acid sequence of the HCV p7 protein or the six peptides comprising the 
corresponding pepmix, all based on HCV strain J4 (genotype 1b) (a). Vaccine antigens were formulated with 
the adjuvant CAF09. CB6F1 mice were vaccinated three times at 2-week intervals (b); control mice received 
CAF09 alone. PBMCs isolated from individual mice were re-stimulated with a p7 peptide pool corresponding 
to the amino acid sequence of the employed vaccine antigen and analyzed by multi-parameter FACS-analysis 
two weeks after the final vaccination. Representative FACS plots indicate the gating strategy on the IFN-γ (top 
panel), TNF-α (middle panel) and IL-2 (lower panel) producing population of CD44+ CD4+ T-cells (c) or 
CD44+ CD8+ T-cells (d). The bar charts show frequencies of p7-specific IFN-γ, TNF-α and IL-2 producing 
CD44+ CD4+ T-cells (e) and CD44+ CD8+ T-cells (f) out of the total CD4+ and CD8+ T-cell population, 
respectively. The data are shown as means and standard errors of the mean (SEM) (n = 4 to 8 mice in each 
vaccine group). *P < 0.05; **P < 0.01.
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Knowing which peptides contain epitopes targeted by vaccination, we pulsed CFSE-labelled target cells with 
peptide #1, #3 or #4 and subsequently injected them i.v. into p7 pepmix (J4) vaccinated C57BL/6 or BALB/c mice 
as indicated on the timeline in Fig. 2c. After eighteen hours, splenocytes were retrieved and vaccine-induced 
killing by T-cells specific for peptide #1, #3 or #4 was determined by measuring the frequencies of remaining 
target cells in vaccinated versus control mice by flow cytometry-analysis, and gating on CFSE-labelled cells 
(Supplementary Figs S3c and S4c). C57BL/6 mice eliminated 18.1% ± 2.2 of target cells pulsed with peptide #4 
compared to 4.2% ± 2.3 in BALB/c mice (Fig. 2c). This corresponds well with the strong CD8+ and CD4+ T cell 
immunity observed in C57BL/6 mice and absent CD8+ T cells in BALB/c mice. Nevertheless, elimination of 
target cells pulsed with peptide #1 (11.2% ± 3.5) or #3 (23.4% ± 2.0), which only contain CD4+ T-cell epitopes, 
suggests that effector mechanisms other than CD8+ T-cells contribute to elimination of target cells in vivo.
Vaccine-induced clearance of liver cells co-expressing HCV-p7 and GFP. In addition to inducing 
vigorous, multifunctional cellular immunity with cytotoxic capabilities, an effective HCV-vaccine should also 
Figure 2. Specific killing by cytotoxic CD4+ and CD8+ T-cells in vivo (a) Mice were vaccinated three times 
at 2-week intervals with HCV p7 protein or pepmix (strain J4) as indicated above the graphs. Splenocytes 
from individual mice were isolated two weeks after the final vaccination and re-stimulated with each of the 
individual peptides spanning the p7 (J4) sequence to map the repertoire of epitope-specific responses. The 
peptide# identifiers are indicated below the x-axis. Bars indicate the total frequency of epitope-specific CD44+ 
CD4+ T-cells (upper panels) and CD44+ CD8+ T-cells (lower panels) able to produce IFN-γ, TNF-α or IL-2 in 
any combination. Data are shown as means and SEM (n = 4 to 6 mice in each vaccine group). (b) Pept#4 (J4)-
specific CD8+ T-cells were further assessed for their ability to co-express CD107 with IFN-γ and/or TNF-α. (c) 
CFSE-labelled target cells from naïve mice were pulsed with single p7 peptides #1, #3 or #4 or left untouched 
and subsequently injected i.v. into controls and p7 pepmix (J4) vaccinated C57BL/6 or BALB/c mice 12 days 
after the final immunization, as indicated on the timeline. Eighteen hours after i.v. injection, the remaining 
population of target cells in in controls or vaccinated mice were identified based on their CFSE-fluorescence and 
MHC-II expression (timeline). The graph shows percent specific killing of target cells pulsed with peptides #1, 
#3 or #4 in individual mice vaccinated with p7 pepmix relative to control mice. Means and SEM are indicated on 
the graph (n = 5 mice in each vaccine group).
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induce T-cells with the ability to infiltrate the liver environment in order to eliminate viral infected hepatocytes. 
This is, however, a challenge not possible to address in any immune competent animal model other than chim-
panzees5,46. Generation of transiently liver-transgenic mice by hydrodynamic injection of DNA solultion has 
been used as a valuable tool to assess vaccine efficacy in terms of T-cell migration to the liver and elimination of 
hepatocytes expressing HCV NS3/4A27,47–50. To ensure liver specific expression of target proteins, we modified 
this approach by constructing plasmids encoding HCV-p7 (J4 or H77) and GFP expressed from a single albumin 
promoter and its upstream enhancer sequence51. Further, to obtain stochiometric expression of the transient 
transgenes, the p7 and GFP sequences were separated by the thosea asigna T2A linker sequence, a foot and 
mouth disease virus (FMDV) 2A-like self-cleaving protease52,53. Initially, mice received PBS, or 1, 10 or 50 µg 
p7(J4)-GFP plasmid by hydrodynamic injection and we subsequently assessed the liver for GFP-expressing cells 
by flow cytometry-analysis three days after the injection. In mice that received the highest dose (50 µg DNA), 
we found 1.8% ( ± 0.7) GFP+ cells. Importantly, in these mice, no GFP expression was observed in the kidney, 
heart, lung or spleen (Supplementary Fig. S5a). Next, after hydrodynamic injection with PBS (Supplementary 
Fig. S5b, upper panel) or 100 µg p7(J4)-GFP (lower panel) we visualized GFP expressing liver cells by fluorescence 
microscopy after co-staining with DAPI. In parallel, unstained cells from these mice were run on flow cytometry 
to identify GFP-expressing cells based on their fluorescence (Supplementary Fig. S5c). Comparable results could 
be obtained by hydrodynamic injection of a similar plasmid construct expressing p7 based on HCV strain H77 
(Supplementary Fig. S5d).
We next evaluated vaccine efficacy by investigating the ability of HCV p7 specific T-cells in clearing liver cells. 
Mice were vaccinated with p7 protein (H77) or p7 pepmix (H77) as outlined in Fig. 3a. Seventeen days after the 
final vaccination, mice were challenged with 100 μg p7(H77)-GFP plasmid DNA by hydrodynamic injection. 
Controls received PBS only. After another five days, flow cytometry-analysis was used to assess the ability of 
vaccinated mice in clearing liver cells co-expressing p7 and GFP. Representative plots show the frequency of 
GFP-expressing liver cells in vaccinated mice that received hydrodynamic injections with PBS (Fig. 3b, upper 
panel) or were challenged with p7(H77)-GFP plasmid (Fig. 3b, lower panel). CAF09 immunized control mice 
injected with either PBS or plasmid were used to outline gates defining GFP- vs. GFP+ liver cells based on their 
fluorescence intensity. We found that p7 pepmix (H77) vaccinated mice cleared transiently transfected GFP+ liver 
cells to a level comparable to the background signal in control mice that received PBS by hydrodynamic injection 
(Fig. 3c). Further, p7 protein (H77) vaccination resulted in a lower but still significant reduction of GFP+ cells 
(Fig. 3c).
As seen in CAF09 immunized mice, transiently transfected liver cells within the GFP+ gate differed in their 
level of GFP expression (Fig. 3b, lower panel, left). Interestingly, it was evident that p7 protein vaccinated mice 
efficiently targeted cells that expressed high levels of transgenes, whereas liver cells within the GFP+ gate, but with 
a lower expression of GFP were cleared to a lesser extend (Fig. 3b, lower panel, middle).
Additionally, to assess the potential of p7 pepmix in cross-protecting against a heterogenous genotype, we vac-
cinated mice with p7 pepmix (H77) and subsequently performed hydrodymic challenge with either p7(H77)-GFP 
or p7(J4)-GFP. Here, we found that significant reduction of GFP+ cells could be achieved four days after challenge 
with the homologous p7(H77), but not the heterologous p7(J4) sequence (Fig. 3d). The lack of cross-reactivity in 
vaccinated mice followed by heterologous challenge may be ascribed to differences between the H77 and J4 p7 
amino acid sequences, which is apparent within each of the six p7 pepmix peptides (Fig. 3e).
HCV p7-specific T cell responses induced by vaccination pre- and post- antigen challenge. Given 
the efficient clearance of antigen presenting target cells in p7 pepmix (H77) vs. p7 protein (H77) vaccinated mice, 
we also evaluated the induced T cell responses after challenge. We detected robust CD4+ and CD8+ T-cell responses 
after p7 pepmix (H77) vaccination, wheras a considerably lower CD4+ T cell response was seen in p7 protein (H77) 
vaccinated mice (Fig. 4a,b, bars).
Compared to pre-challenge responses, we observed elevated magnitudes of cytokine producing CD4+ 
T-cells in p7 pepmix vaccinated mice, whereas CD8+ responses remained unaltered (compare to Supplementary 
Fig. S6a,b). It is unclear to which extent the magnitude of T cell responses are influenced by the challenge or 
merely reflects the kinetics of the vaccine induced response.
Boolean gating revealed that the majority of antigen specific CD4+ and CD8+ T-cells in p7 pepmix vaccinated 
mice were able to co-produce INF-γ and TNF-α (Fig. 4a,b, pies), indicating that the response is skewed towards 
an effector-like response, whereas a larger proportion of IFN-γ, TNF-α and IL-2 co-producing CD4+ T-cells 
observed in p7 protein vaccinated mice suggest a response with proliferative potential.
Detailed analysis on CD4+ T-cells in mouse models propose the ability of proliferative PD-1hiKLRG1lo to 
differentiate into high-capacity cytokine producing PD-1intKLRG1hi cells54. We therefore analyzed the PD-1 and 
KLRG1 expression on cytokine producing T-cells and found CD4+ T cells in p7 pepmix (H77) vaccinated mice 
to be skewed towards a PD-1intKLRG1hi phenotype after surrogate challenge (Supplementary Figs S6c vs. S7a). 
Compared to their PD-1hiKLRG1lo counterparts, these cells were also far more efficient in producing INF-γ and 
TNF-α (Supplementary Figs S6e and S7c). Contrary, the PD-1hiKLRG1lo subset, that clearly was the dominating 
one in p7 protein (H77) vaccinated mice, expressed higher levels of IL-2 and CD62L. Such pattern of differen-
tial cytokine production linked to PD-1 and KLRG1 expression was not as apparent on the CD8+ T-cell level 
(Supplementary Figs S6d,f and S7b,d).
Compared to PMBCs, the frequncy of antigen-specific CD4+ T-cells found in the liver was considerably 
reduced in p7 pepmix (H77) vaccinated mice (Fig. 4c). Here, cytokine producing cells displayed a lower degree of 
multifunctionality than circulating T-cells (pie charts). Interestingly, minute CD8+ T-cell responses were detected 
in the liver of p7 protein (H77) vaccinated mice after challenge (Fig. 4d). Contrary, no p7 specific CD8+ T-cells 
were detected in this vaccine group when PBS only was administered by hydrodynamic injection (Supplementary 
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Figure 3. HCV p7 vaccination reduced GFP-expression in the liver after surrogate challenge. (a) The diagram 
indicates time points for vaccination, bleeding, surrogate challenge and termination of the experiment. (b) 
Representative FACS-plots shows gating of GFP-expressing liver cells from CAF09 versus p7 protein and 
pepmix (strain H77) vaccinated mice five days after hydrodynamic injection (H.I.) of PBS (upper panel) or 
100 µg p7(H77)-GFP plasmid (lower panel). (c) The bar charts show frequencies of GFP-expressing liver-cells in 
vaccinated mice after surrogate challenge. Control mice that received hydrodynamic injection with PBS alone, 
consisted of 3-4 mice from each vaccine group. Bars represent means and standard errors of the mean (SEM) 
(n = 7 to 12 mice in each group). *P < 0.05; **P < 0.01. (d) Reactivity of p7 pepmix (H77)-induced immunity 
with liver cells challenged with either p7(H77)-GFP or p7(J4)-GFP plasmid (homologous vs. heterologous relative 
to the vaccine antigen) as indicated below the chart, was performed 4 days after hydrodynamic injection. Naïve 
control mice were challenged with PBS alone. Bars represent means and standard errors of the mean (SEM) (n = 7 
to 8 mice in each vaccine group; 3 naïve controls received PBS by H.I.). **P < 0.01. (e) Schematic presentation of 
the HCV p7 pepmix vaccine with the six overlapping peptides aligned with the p7 (H77) amino acid sequence. 
Black marks and amino acids shaded with grey indicate sequence variations compared to the J4 strain.
7Scientific RepoRtS |         (2019) 9:14085  | https://doi.org/10.1038/s41598-019-50365-z
www.nature.com/scientificreportswww.nature.com/scientificreports/
Fig. S8). Taken together, our data suggest that p7 protein and pepmix induce T-cell responses that differ not only 
in magnitude but also display distinct cytokine profiles and functionalities.
Discussion
In the present study, we have established HCV p7 as a potential vaccine antigen. Our data show that multifunc-
tional CD4+ and CD8+ T-cell responses could be generated by vaccination with overlapping peptide panels cover-
ing HCV p7 sequences formulated in cross-priming, cationic nanoparticles. Further, using a developed surrogate 
challenge model we demonstrated that vaccinated mice could clear liver cells expressing HCV p7.
Despite the heterogeneity of p7 across HCV genotypes, certain amino acids within the transmembrane helices 
and cytoplasmic loop are highly conserved across HCV genotypes39,42. Cyclic amino acids such as tryptophan 
(W) and tyrosine (Y) are considered important structure-function determinants for viroporins of influenza A 
and HIV55,56. This may also be the case for HCV p7 as substitution of the highly conserved tryptophan and 
tyrosine residues at position 776 and 788, respectively, dramatically reduced infectivity and release of new viri-
ons39. Several other residues of p7 are subject to mutational escape from T-cells as demonstrated in chimpan-
zees experimentally infected with HCV15,41,57. Although confounding factors that potentially mask detection of 
p7 specific T-cells in peptide re-stimulation assays include the presence of non-responsive, exhausted T cells 
or re-stimulation with non-autologous viral sequences, immune pressure by T-cells targeting p7 has also been 
demonstrated in patients chronically infected with HCV58. Here the epitope sequence FYGMWPLL (residue 
790–797 of H77) is recognized in patients with a Cw7 or A29 HLA background. Interestingly, several studies of 
chimpanzees infected with different HCV clones showed that immune selection pressure led to substitution of 
the methionine (M) residue found within this region15,41,57. These observations could indicate the presence of 
one or more promiscuous T-cell epitopes recognized across a broad genetic background. In this context, it is also 
noticeable that the sequence FYGMWPL (H77) and FYGVWPL (J4) as well as the conserved tyrosine residue 788 
is present in peptide #4 of the HCV p7 pepmix, which induced both CD4+ and CD8+ T cell responses in CB6F1 
mice (Fig. 2 and Supplementary Fig. S2). Thus, although broad T-cell responses cannot be induced with HCV p7 
Figure 4. Frequencies and functional characterization of antigen-specific cytokine producing T-cells from 
HCV p7 protein or p7 pepmix (H77) vaccinated mice after surrogate challenge. Five days after challenge with 
p7(H77)-GFP plasmid, PBMCs (a,b) and liver cells (c,d) were isolated from individual mice, re-stimulated with 
a pool of overlapping p7(H77) peptides, and analyzed by multi-parameter IC-FACS to assess the frequencies 
of p7-specific IFN-γ, TNF-α and IL-2 producing CD44+ CD4+ T-cells (a,c) or CD44+ CD8+ T-cells (b,d) 
out of the total CD4+ or CD8+ T-cell population, respectively, 5 days after surrogate challenge. Pie charts 
show the distribution of IFN-γ producing CD44+ CD4+ or CD44+ CD8+ T-cells divided into three distinct 
subpopulations based on their ability to co-produce TNF-α alone or in combination with IL-2. Empty pies 
indicate total cytokine responses below a 0.2% cut-off. Data are shown as means and standard errors of the 
mean (SEM) (n = 7 to 12 mice in each vaccine group). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
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due to its relatively small size, it represents an interesting vaccine antigen that should be examined further and 
might be useful in combination with other antigens.
Vaccine strategies pursuing to target additional epitopes not targeted by an infection-driven response have 
been used in several systems against HCV, HIV, lymphocytic choriomeningitis virus (LCMV), human papillo-
mavirus (HPV) and M. tuberculosis (M.tb.). Such strategies exploit truncated or fragmented antigens rather than 
injection- or expression of full-length proteins to influence antigen processing and presentation by APCs43,59–64. 
Further, substitution or removal of certain amino acid residues or sequences flanking potential T-cell epitopes 
have been shown to enhance induction of particularly CD8+ T-cell responses, which would otherwise not be 
supported through natural processing of the corresponding full-length antigen65–67. Concordant with these obser-
vations, immunization with the full-length HCV p7 protein only induced CD4+ T-cells, whereas p7 pepmix 
consisting of 6 overlapping peptides of the identical sequence generated robust CD4+ and CD8+ T-cell responses.
Whereas multifunctional, cytotoxic CD8+ T-cells are regarded as the primary mediators of clearance of HCV 
infected cells, the role of cytotoxic CD4+ T-cells is less well studied although there is evidence of immune pressure 
on the HCV genome exerted by these cells17. It has, however, become clear that specialized CD4+ T-cell effector 
subsets with direct cytolytic capacity can be induced to target a number of viral infections, e.g. HIV, poliovirus 
and influenza in a granzyme B, perforin or FasL mediated manner68–71. Accumulation of cytotoxic CD4+ T-cells 
is also seen in persistent HCV infection72. Exposure to high levels of antigen in the presence of IL-2 appears to 
favor differentiation into cytotoxic CD4+ T-cells, which typically co-express IFN-γ and TNF-α73. In our study, 
vaccination with HCV p7 pepmix generated CD4+ T-cells with a distinguished IFN-γ+TNF-α+ double positive 
cytokine profile and a phenotypic effector-like signature.
We here found that individual transfected liver cells within the GFP+ gate differed in their level of GFP expres-
sion and thus presumably also expression of the HCV p7 protein (Fig. 3b). Although the HCV p7 protein vacci-
nated mice could target p7 and GFP co-expressing cells, it was evident, that GFP+ cells expressing higher levels 
of transgenes, were more efficiently cleared than GFP+ cells with a lower expression of transgenes. It is therefore 
likely that induction of CD8+ T-cells is a prerequisite for elimination of liver cells co-expressing lower levels of p7 
and GFP, which could explain the enhanced clearance of GFP+ liver cells in p7 pepmix vaccinated mice.
Although vaccination with HCV p7 protein only induced CD4+ T-cell responses, minute CD8+ T-cell 
responses were detected in the liver of these mice, but only after hydrodynamic challenge with plasmid-DNA 
(and not PBS). As IL-2 producing CD4+ T-cells play a central role in antiviral immunity, also by providing help 
to induce and maintain CD8+ T-cell immunity, it could therefore be speculated whether CD4+ T-cells induced 
through protein vaccination was a prerequisite for induction of CD8+ T-cells upon endogenous p7-expression74.
CD8+ T-cells may therefore account for clearance of HCV p7-GFP expressing liver cells in both p7 protein and 
pepmix vaccinated mice. Direct interaction of CD4+ T-cells with target cells requires expression of MHC class II 
which is not normally expressed on parenchymal cells. However, aberrant expression of MHC class II by hepato-
cytes has been observed during clinical hepatitis75,76, hepatocellular carcinoma (HCC)77,78, in HCC cell lines79,80 
or primary hepatocytes under inflammatory stress conditions81. Endogenous expressed antigens can readily enter 
the MHC class II pathway, and hepatocytes expressing MHC class II together with co-stimulatory B7.1 molecules 
(CD80) have been shown to activate both Th1 and Th2 CD4+ T-cells in a mouse model82,83. Thus, although the 
prerequisites for direct hepatocyte-CD4+ T-cell interaction may be met, it remains to be determined whether 
hepatocytes infected with HCV can present viral antigens on MHC class II and hereby be targeted directly by 
CD4+ T-cells.
As the CAF09 adjuvant also supports induction of humoral responses, other effector mechanisms such as 
antibody-dependent cellular cytotoxicity (ADCC), may also contribute to the clearance of target cells in vivo84,85. 
Although the contribution of ADCC in clearance of HCV remains to be studied in detail, ADCC represents an 
important asset in cancer immunotherapy and is also believed to contribute to clearance of HIV infection86,87.
It would be of interest in future studies to address these questions experimentally, e.g. in a fully immune 
competent small animal challenge model with an HCV-related hepatotropic virus, such as the Norway rat hepaci 
virus (NrHV)88,89. Further, this model could serve as an important tool for future evaluation of a NrHV-based p7 
pepmix vaccine, e.g. also combined with other viral antigens, and its ability to overcome viral immune evasion 
mechanisms including mutational escape. The present study serves as a proof of principle that efficient cellu-
lar immunity against HCV p7 can be induced by vaccination with peptide-based cross-priming nanoparticles. 
Importantly, by including additional peptides in the library, the pepmix vaccine can be expanded to cover mul-
tiple HCV sub- or genotype sequences of p7. Finally, this approach could be further developed by targeing p7 in 
combination with other antigens, such as peptides covering HCV NS3, to ensure generation of a broader T-cell 
repertoire targeting several conserved regions of the virus, which is anticipated to be a prerequisite for efficient 
protection against HCV43.
Materials and Methods
Mice. Six to eight week old female CB6F1 (C57BL/6 X BALB/c), C57BL/6, and BALB/c mice were purchased 
from Harlan Scandinavia, and housed in the experimental-animal facilities at Statens Serum Institut. All handling 
and procedures were performed by authorized personnel in accordance with the European community Directive 
86/609 and approved by the Danish Council for Animal Experiments.
Vaccines. p7 deduced from the cloned HCV strains J4 (genotype 1b)44,90 or H77 (genotype 1a)91 were used 
as vaccine antigens. Panels of five 20-mer and one 13-mer peptides covering the entire p7 sequence of J4 or H77 
were used in the pepmix vaccines and the corresponding full-length p7 proteins were synthesized as polypep-
tides. Lyophilized peptides were reconstituted in DMSO (10 mg/ml). Vaccine antigens were prepared with the 
cationic adjuvant formulation CAF09 (250 µg DDA/50 µg MMG/50 µg Poly(I:C)/dose). Unless stated otherwise, 
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mice received 10 µg p7 protein or 10 µg of each peptide in pepmix vaccines. All vaccines were administrated intra-
peritoneally at a volume of 0.2 ml, three times at two-week intervals.
Cell preparations. Blood was obtained by periorbital puncture or via the facial vein, and PBMCs were iso-
lated by gradient centrifugation with Lympholyte (Cedarlane) as per manufacturers protocol. Splenocytes and 
cells from kidneys were obtained by homogenization through a 100 µm nylon cell strainer followed by hypotonic 
lysis of red blood cells in 0.84% NH4Cl and two washes with PBS. Cells from lung and heart were isolated by 
the same procedure as described above, following digestion of tissue in 1 mg/ml collagenase IV for 45 minutes. 
Livers were perfused and homogenized for 2 × 25 seconds on gentle MACS dissociator in C-tubes containing 5 ml 
RPMI, 0.4 mg/ml collagenase IV and 0.5 µg/ml DNase 1, and the tissue suspensions was then incubated 25 min-
utes at 37 °C with frequent shaking. The suspension was then forced through a 100 µm cell strainer, washed in 
PBS, and resuspended in 4.5 ml 0.84% NH4Cl. After five minutes, liver cells were washed in twice in RPMI. Cells 
from any tissue were resuspended in media (RPMI 1640 supplemented with 1 mM glutamine, 1% pyruvate, 1% 
penicillin-streptomycin, 1% Hepes and 10% FBS) and cell cultures were performed in 96-well V-bottom plates.
Plasmids. VectorBuilder 1.0 software (Cyagen) was used to design p7(J4)-GFP and p7(H77)-GFP plasmids 
with a coding sequence containing codon optimized HCV p7 (J4 or H77) and eGFP sequences separated by 
a T2A linker sequence under control of an albumin promotor and its upstream enhancer sequence51,92. E. coli 
Stbl3 cultures cloned with the expression vectors (Cyagen) were cultured and plasmid DNA was purified using 
Endofree plasmid Giga kit (Quiagen) as per manufacturer’s instructions.
Surrogate challenge. Transient transfection of liver cells was performed by hydrodynamic injection of plas-
mid DNA, as described elsewhere93,94. In brief, fully anesthetized mice received volumes of 1.6 ml PBS containing 
0, 1, 10, 50 or 100 µg p7(J4)-GFP or p7(H77)-GFP plasmid injected into the tail vein within 6–10 seconds at a 
constant rate.
Microscopy. Liver cells were fixed 15 minutes at 4 °C in Cytofix kit (BD Pharmingen) and washed twice in 
PBS followed by nuclei staining in Hoechst 33342 at 1:5000 in 10 minutes. 1–1.1E6 cells per well were allowed 
to settle overnight in 6-well plates at 4 °C and were visualized on a Zeiss AXIO observer Z1 system with minor 
adjustment of contrast in Zen 2 core v.2.4 software.
Flow cytometry. For re-stimulation assays, cells were co-incubated with peptides (individually or as a pool 
of the 6 peptides spanning the p7 sequence; 2 µg/ml of each) and CD28/CD49d antibodies (clone 37.51 and 
9C10; MFR4.B, BD Pharmingen) in media in 96-well plates for one hour at 37 °C followed by six hours incuba-
tion in the presence of 10 µg/ml brefeldin A. Cells were washed in FACS-buffer (PBS containing 1% FBS) and 
subsequently stained for surface markers (30 min at 4 °C) followed by washing, permeabilization using Cytofix/
Cytoperm kit (BD Pharmingen) as per manufacturers protocol, and intracellular staining (30 min at 4 °C). For 
six-color flow cytometry-analysis anti-CD4-APC-Cy7 (clone GK1.5), anti-CD8-PerCP-Cy5.5 (clone 53–6.7) and 
anti-CD44-FITC (clone IM7) for surface staining were diluted 1:600 in FACS-buffer and anti-IFN-γ-PE-Cy7 
(clone XMG1.2), anti-TNF-α-PE (clone MP6-XT22) and anti-IL-2-APC (clone JES6-5H4) for intracellular stain-
ing were diluted 1:200 in PermWash buffer (BD Pharmingen). Cells were subsequently washed and analyzed on 
a six-color FACSCanto instrument (BD Biosciences).
For 10-color flow cytometry-analysis, surface staining was performed with anti-CD4-BV510 (clone 
RM4-5, Biolegend), anti-CD8-PerCP-Cy5.5 and anti-CD44-Alexa700 (clone IM7, Biolegend) diluted 1:600, 
anti-CD3-BV650 (clone 17A2, Biolegend), anti-KLRG1-BV711 (clone 2F1, eBiosciences) and antiCD62L-FITC 
(clone MEL-14, BD Pharmingen) diluted 1:200 and anti-PD-1-PE-Cy7 (clone RMP1, Biolegend) diluted 1:100 
in FACS-buffer. Intracellular IFN-γ, TNF-α, and IL-2 were stained with antibodies and concentrations identical 
to those used in the 6-color panel. FSC-A/SSC-A gating to identify lymphocytes was performed after doublet 
exclusion based on their FSC-A/FSC-H properties. These were further gated into CD3+ CD4+ or CD3+ CD8+ 
T cells followed by gating of CD4+ CD44+ and CD8+ CD44+ populations into IFN-γ, TNF-α and IL-2 pro-
ducing T-cells. Boolean gates were applied to divide IFN-γ producing cells into three distinct subpopulations 
based on their ability to co-produce TNF-α alone or in combination with IL-2. Finally, Boolean gating was also 
employed to select antigen specific T-cell producing any cytokine, which were further gated into PD-1hiKLRG1lo 
and PD-1intKLRG1hi subsets analyzed for their expression level of IFN-γ, TNF-α, IL-2 and CD62L based on their 
median fluorescence intensity (MFI).
For analysis of CD107 expression, cells were prepared as described above, with the exception being 
anti-CD107a-FITC (clone 1D4B, BD Pharmingen), which was co-incubated during p7 (J4) peptide# 4 restim-
ulation at a 1:100 dilution. CD8-APC-Cy7 (clone 53–6.7, BD Pharmingen), anti-IFN-γ-PerCP-Cy5.5 (clone 
XMG1.2, eBiosciences) and anti-TNF-α-allophycocyanin (clone MP6, BD Pharmingen) were all in 1:200 dilu-
tions. Boolean gating was applied to CD8+ T-cells to determine the degree of co-production of IFN-γ and TNF-α 
by CD107+ cells.
GFP-expression of liver cells was performed on unstained cells fixed 15 minutes at 4 °C in Cytofix and washed 
twice in FACS-buffer before analysis on a BD Fortessa instrument. Large cells were gated based on their FSC-A/
FSC-H profile excluding lymphocytes and were further gated into a FSC-A/SSC-Ahi profile enriched of hepat-
ocytes95. GFP+ cells were identified based on their FITC/FSC-H profile. All flow cytometry data were analyzed 
using FlowJo software v10.1 (Tree Star Ashland).
In vivo cytotoxicity. Splenocytes isolated from naïve C57BL/6 or BALB/c mice were divided into three frac-
tions and labelled with CFSE at either 0.8 µM (CFSElow), 4 µM (CFSEmid) or 20 µM (CFSEhigh) in PBS at room 
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temperature. After 10 minutes, ice-cold FBS was added to a final concentration of 30% and the cells were washed 
in full media. CFSElow and CFSEhigh fractions from C57BL/c mice were pulsed with 10 µg/ml p7 (J4) peptide #4 
and #1, respectively. The CFSEmid fraction was left unpulsed. The three fractions of cells were then mixed in 1:1:1 
ratio, washed three times in RPMI 1640, and filtered through a 100 µm nylon mesh before they were injected 
into immunized C57BL/6 mice at volumes of 300 µl containing 3.3E7 cells/ml 12 days after the final vaccination. 
CFSElow and CFSEhigh fractions from BALB/c mice peptide #4 and #3, respectively, but otherwise treated iden-
tically as described above, before they were injected into vaccinated BALB/c mice. Eighteen hours after injec-
tion of the labelled cells, splenocytes were recovered from mice and labelled with anti-MHC-II-PerCP-Cy5.5 
(BioLegend, clone M5/114.15.2) and analyzed on flow cytometry. Cells were gated based on their FSC-A/FSC-H 
properties and the three cell fractions could be distinguished based on their CFSE profile. Lysis of peptide-pulsed 
target cells relative to unpulsed cells was determined using the equation: 1 − ((% peptide pulsed cellsvaccinated mice/% 
unpulsed cellsvaccinated mice) − (% peptide pulsed cellscontrol mice/% unpulsed cellscontrol mice)).
In silico epitope predictions of CD8+ T-cell epitopes. CD8+ T-cell epitopes within p7 peptide #4 
derived from the HCV J4 or H77 sequences were performed using the T-cell epitope processing and prediction 
tool provided by the Immune Epitope Database (IEDB) Analysis Resource (http://tools.iedb.org/processing/) 
employing the NetMHCpan 3.0 algorithm.
Statistical analysis. Analysis of variance (ANOVA) followed by Tukey´s posttest was used in all assays to com-
pare differences between multiple vaccine groups. Statistically significant differences are marked with asterisks in 
figures and explained in the figure legends. All statistical analysis was performed using Prism 6 software (GraphPad).
Data Availability
All data generated or analysed during this study are included in this published article and its Supplementory 
Information files.
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